Cat. No. 5864
Alternative Names: Tasmar, Ro 40-7592
Chemical Name: (3,4-Dihydroxy-5-nitrophenyl)(4-met
Biological ActivityCOMT inhibitor. Inhibits both brain and peripheral COMT. Also binds transthyretin (TTR) with high affinity (Kd1 and Kd2 values are 21 and 58 nM, respectively). Inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Sant'Anna et al (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat.Commun. 7 10787. PMID: 26902880.
Männistö et al (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br.J.Pharmacol. 105 569. PMID: 1628144.
If you know of a relevant reference for Tolcapone please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Tolcapone from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Tolcapone, supplier, catechol, O-methyl, transferase, inhibitors, inhibits, COMT, orally, bioavailable, high, affinity, TTR, binding, transthyretin, aggregation, Ro40-7592, Tocris Bioscience, Catechol O-Methyltransferase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent farnesyl transferase inhibitorA 196
Potent and selective SUV420H1/H2 inhibitorGSK 343
Potent and selective SAM-competitive EZH2 inhibitorBRD 4770
G9a inhibitor and S-adenosyl methionine mimetic; cell permeableLys-CoA
Selective p300 inhibitorUNC 2399
Biotinylated UNC 1999 (Cat.No. 4904)PF 06726304 acetate
Highly potent and SAM-competitive EZH2 inhibitorGSK 591 dihydrochloride
Potent and selective PRMT5 inhibitor
September 27 - 30, 2017